Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Annual Report & Accounts

21st Sep 2012 16:26

RNS Number : 9027M
ABCAM Plc
21 September 2012
 



For immediate release

21 September 2012

 

 

ABCAM PLC

("Abcam" or "the Company")

 

 

Annual Report and Accounts

 

Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that its Annual Report and Accounts for the year ended 30 June 2012 has been posted to shareholders and is being made available at the Company's investor relations website, www.abcamplc.com.

 

For further information please contact:

 

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

Numis Securities - Nominated Advisor and Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Advisor

James Black - Corporate Broking

Peel Hunt LLP - Joint Broker

+ 44 (0) 207 418 8900

Andy Crossley - Corporate Broking

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes for editors

 

About Abcam plc

 

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.

Abcam now has an online catalogue of more than 95,000 products sourced from more than 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website, www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science reagents company.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSSESFIFFESEEU

Related Shares:

ABC.L
FTSE 100 Latest
Value8,275.66
Change0.00